Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of defensins to aspect of preparation of medicine for treating metabolic syndrome

A metabolic syndrome and defensin technology, applied in the field of biomedicine, can solve the problems related to vitamin D deficiency metabolic syndrome and increased intestinal energy absorption

Active Publication Date: 2015-10-14
SQ BIOPHARMA INC
View PDF2 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] 5. Correlation between vitamin D deficiency and metabolic syndrome
Metagenomic analysis reveals an increase in genes encoding polysaccharide-decomposing polysaccharides, including glycogen hydrolases, in the gut microbiota of obese mice, leading to increased intestinal energy absorption

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of defensins to aspect of preparation of medicine for treating metabolic syndrome
  • Application of defensins to aspect of preparation of medicine for treating metabolic syndrome
  • Application of defensins to aspect of preparation of medicine for treating metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121] Example 1. Establishment of a new metabolic syndrome model and evaluation of vitamin D treatment effect.

[0122] SPF grade experimental mice, including Babl / C or C57 / B6 and other strains, weighing 20-25g. At room temperature, the experimental animals were given free access to food and water. Four diets were fed for 18 weeks (n=20 per condition).

[0123] C: Control, 12% of the calories in the food comes from animal fat, and the content of vitamin D3 is 1000IU / kg.

[0124] VDD: Vitamin D-deficient common food, 12% of calories come from animal fat, no added vitamin D.

[0125] HFD: High-fat feed, 60% of the calories are derived from animal fat, and the content of vitamin D3 is 1000IU / kg.

[0126] HFD+VDD: Vitamin D deficiency in high fat diet.

[0127] For the two conditions of vitamin D deficiency, VDD+HFD and VDD mice, try to avoid light during feeding (the breeding cage can isolate UV light). The remaining mice received natural diurnal light. The animal model i...

Embodiment 2

[0139] Embodiment 2: oral administration of alpha defensin 5 to treat metabolic syndrome.

[0140] In order to prove the curative effect of defensin 5 on metabolic syndrome, we first established a "high fat + vitamin D deficiency" animal model, and then administered DEFA5 to the mice orally. The dose is 5-10 micrograms / time (n=6), twice a week, four times in total. As a control, the same volume of water was given to metabolic syndrome mice. In the experiment, we also used a mutant of alpha defensin, whose primary structure is mut-Defa5:ATSYARTGESATAESLSGVAEISGSLYSLSAE (this mutant does not contain the key disulfide bond and key arginine residue of defensin 5 structure) .

[0141] During treatment, monitor body weight, blood sugar, and the balance of the flora ecology in the stool. After treatment, the mice lost weight and returned to normal. Ten days after the treatment, the mice were killed and the indicators were measured.

[0142] (1) Oral administration of alpha def...

Embodiment 3

[0151] Embodiment 3: the application of oral defensin 5 or defensin 6, or vitamin D as a drug for the treatment of metabolic syndrome.

[0152] Defensins are human-derived antimicrobial peptides secreted by intestinal Paneth cells, including DEFA5 and DEFA6. One of the cores of this application is to balance the intestinal flora by oral administration of alpha defensin 5 / 6, thereby improving / treating metabolic syndrome, type 2 diabetes and its complications.

[0153] Through animal experiments, our work shows that oral administration of human DEFA5 can rebalance the intestinal flora, reduce endotoxin into the blood, reduce systemic inflammation, and improve insulin resistance, thereby treating metabolic syndrome. In the mouse model, we found that the administration of 5-10 micrograms (5-10μg) / time of human DEFA5 can have obvious effects, including balancing intestinal flora and improving blood sugar.

[0154] Thus, dosages in humans can be as low as ten milligrams (10 mg). T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention mainly relates to an application of defensins to an aspect of preparation of a medicine for treating metabolic syndrome. Inventiveness and exploitativeness of the invention are reflected in that human derived alpha defensins 5 and 6 is supplemented via oral administration to balance intestinal flora ecology, so that system inflammation is reduced; insulin resistance is relieved; the fatty liver is ablated; and blood fat and blood sugar are reduced. The invention further provides a method for preparing the alpha defensins 5 and 6, and the application of the alpha defensins 5 and 6 to the medicine for treating related diseases.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of a defensin in the preparation of drugs for treating metabolic syndrome. Background technique [0002] 1. Incidence and pathogenesis of metabolic syndrome [0003] Metabolic syndrome (X-syndrome), manifested as hyperlipidemia, hypercholesterolemia, hypertension, fatty liver, obesity and diabetes, has become widespread all over the world. With the development of society and economy, the change of dietary structure and lifestyle, metabolic syndrome has increased dramatically in China. In the United States, one-third of the adult population is obese or overweight and presents with a prediabetic state, a trend that is also observed worldwide [1]. In 2004, approximately 178 million people had diabetes, and it is expected to reach 366 million in 2030. According to reports, the prevalence of metabolic syndrome among adults in my country is about 14-1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P3/00A61P1/00A61P3/06A61P1/16A61P3/10A61P9/00A61P13/12A61P27/02A61P17/00A61P3/04A61P9/12A61P5/50
Inventor 韩源平宿丹梅
Owner SQ BIOPHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com